The RNA Targeting Small Molecules Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The RNA Targeting Small Molecules Therapeutics Market:
https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report
According to The Business Research Company’s RNA Targeting Small Molecules Therapeutics Global Market Report 2024, The rna targeting small molecules therapeutics market size has grown exponentially in recent years. It will grow from $1.06 billion in 2023 to $1.45 billion in 2024 at a compound annual growth rate (CAGR) of 37.0%. The growth in the historic period can be attributed to drug discovery and development, rising prevalence of rna-related diseases, government and private funding, pharmaceutical industry interest, rna therapeutics success stories.
The rna targeting small molecules therapeutics market size is expected to see exponential growth in the next few years. It will grow to $5.09 billion in 2028 at a compound annual growth rate (CAGR) of 36.9%. The growth in the forecast period can be attributed to precision medicine and personalized therapies, rise in rna biomarker identification, expanding rna target spectrum, increasing funding and investments, application in rare diseases. Major trends in the forecast period include advancements in screening technologies, antisense oligonucleotides dominance, small molecule rna binders, rna therapeutics in neurological disorders, gene editing with crispr-cas9.
The increasing number of cancer cases is expected to propel the growth of the RNA-targeting small molecule therapeutics market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. Cancer is treated with RNA-targeting small molecules created and investigated to target RNA molecules associated with cancer selectively. For instance, in January 2022, according to research published by the American Cancer Society, a US-based health organization, in the US, 609,360 cancer deaths and 1.9 million new cancer cases are anticipated in 2022. It is about 1,670 fatalities each day. Therefore, the increasing number of cancer cases is driving the growth of the RNA-targeting small molecule therapeutics market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp
The rna targeting small molecules therapeutics market covered in this report is segmented –
1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings
2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications
3) By Application: Drug Discovery, Oncology Research, Disease Identification
4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users
Strategic partnerships are a key trend gaining popularity in the RNA-targeting small molecule therapeutics market. Major companies operating in the RNA-targeting small molecule therapeutics market are undergoing partnerships to develop a new relationship in which two or more organizations develop innovative products. For instance, in June 2022, Otsuka Pharmaceutical Co. Ltd., a Japan-based pharmaceutical manufacturing company, collaborated with xFOREST Therapeutics Co. Ltd., a Japan-based developer of drug discovery platforms. With this partnership, xFOREST will offer Otsuka with its Forest technology to advance systemic small-molecule drug discovery research focusing on RNA structures. Furthermore, in March 2021, Evotec SE, a Germany-based drug discovery and development company, entered a strategic alliance with Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company. Both companies aim to discover and develop RNA-targeting small molecules with this alliance.
The rna targeting small molecules therapeutics market report table of contents includes:
1. Executive Summary
2. RNA Targeting Small Molecules Therapeutics Market Characteristics
3. RNA Targeting Small Molecules Therapeutics Market Trends And Strategies
4.RNA Targeting Small Molecules Therapeutics Market analysis
5.RNA Targeting Small Molecules Therapeutics Market Size And Growth
6.RNA Targeting Small Molecules Therapeutics Segmentation
7.RNA Targeting Small Molecules Therapeutics Regional And Country Analysis
.
.
.
27.RNA Targeting Small Molecules Therapeutics Competitive Landscape And Company Profiles
28.RNA Targeting Small Molecules Therapeutics Key Mergers And Acquisitions
29.RNA Targeting Small Molecules Therapeutics Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Sanofi S.A.
- AstraZeneca PLC
- Eli Lilly and Company
- Amgen Inc.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
